AMAklilu Getachew Mamo

Aklilu Getachew Mamo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aklilu Getachew Mamo has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Abdulber Seid

    Affiliation Department of Educational Planning & Management, College of Education & Behavioral Sciences, Wolkite University, Wolkite, Ethiopia

    1 shared publication
  • Abdulsemed Worku Nida

    Department of Internal Medicine, School of Medicine, College of Health Sciences, Wolkite University, Wolkite, Central Ethiopia Region, Ethiopia

    1 shared publication
  • Ahmed Zeynudin

    School of Medical Laboratory Science Faculty of Health Sciences Institute of Health Jimma University Jimma Oromia Regional State Ethiopia ju.edu.et

    1 shared publication
  • Andrea Sciarretta

    Department of Agricultural, Environmental and Food Sciences, University of Molise, Campobasso, Italy

    1 shared publication
  • Bisrat Fikadu

    Affiliation Department of Medical Laboratory Sciences, College of Medicine and Health Sciences, Wolkite University, Wolkite, Ethiopia

    1 shared publication
  • Dejene Gebre Gobena

    School of Medical Laboratory Science, Health Institute, Jimma University, Jimma, Ethiopia

    1 shared publication

Latest Publications

  • Open Access

    Ethiopia’s Journey Towards Eliminating Human Onchocerciasis: Challenges and Opportunities

    by Aklilu Getachew Mamo, Ahmed Zeynudin, Andrea Sciarretta, Getnet Atenafu, Yibeltal Aschale, Delenasaw Yewhalaw

    Ethiopia bears one of the highest burdens of onchocerciasis worldwide; a neglected tropical disease (NTD) caused by Onchocerca volvulus . Simulium damnosum sensu lato (s.l.) is the primary vector of transmission, although Simulium ethiopiense may also contribute to transmission. Since 2012, the Ethiopian Onchocerciasis Elimination Program has implemented annual or biannual mass drug administration (MDA) of ivermectin as its principal intervention to target the microfilarial stage of the parasite. This strategy has achieved substantial progress in reducing transmission and remains the cornerstone of the national effort to eliminate onchocerciasis by 2030. However, current evidence on the existing challenges and potential opportunities to enhance and sustain elimination efforts is limited. This review therefore explores the key barriers to elimination and highlights opportunities to accelerate progress toward the national elimination goal. This review demonstrates that, although substantial progress has been made, current interventions continue to encounter several challenges. These include the limited integration of vector control as a complementary strategy, inadequate entomological data, the absence of context‐specific criteria for monitoring and evaluating disease transmission, the emergence of drug‐resistant parasite strains and insecticide‐resistant vectors, persistent cross‐border transmission, and the withdrawal of financial support from key donors. Nevertheless, the World Health Organization’s (WHO) strategy to implement context‐based monitoring and evaluation, combined with the adoption of tailored interventions informed by scientific evidence and lessons learned from successful elimination initiatives in South and Central America, offers significant opportunities for further advancement. To sustain current achievements and accelerate elimination efforts, Ethiopia will require continued political commitment, increased domestic financing, meaningful community engagement, strengthened research on vaccines, macro‐ and microfilaricidal agents, vector biology, and transmission dynamics, as well as expanded vector control interventions complementary to community‐directed treatment with ivermectin (CDTI). These efforts will be essential to achieve the ultimate goal of eliminating human onchocerciasis (HO) from Ethiopia once and for all.

  • Open Access

    Prevalence and determinants of erectile dysfunction among diabetic patients attending to selected governmental hospitals, Gurage Zone, Central Ethiopia Region, Ethiopia: A prospective cross-sectional study

    by Seid Abrar, Shiferaw Bekele Woyesa, Abdulsemed Worku Nida, Yaregal Asres, Aklilu Getachew Mamo

    Diabetic men have been reported to have a 3-fold increased risk of developing erectile dysfunction (ED). However, no studies have been conducted in our study area to assess the prevalence and determinants of ED among diabetic patients. Therefore, this study was aimed to determine the prevalence and determinants of ED among diabetic patients attending selected governmental hospitals in Gurage Zone, Central Ethiopia Region. A hospital-based cross-sectional study was conducted involving 320 diabetic patients who attended follow-up visits between September 1 to December 30, 2020. Data on socio-demographic, clinical, and lifestyle characteristics were collected using a structured questionnaire. Anthropometric measurements and blood pressure were obtained in accordance with standard guidelines. Erectile function was assessed using the International Index of Erectile Function-5. Fasting blood glucose and lipid profiles were analyzed using the A25 BioSystems clinical chemistry analyzer. Data entry and analysis were performed using the Statistical Package for the Social Sciences (SPSS) version 20. Multivariable logistic regression analysis was used to identify independent predictors of ED. Of the 320 diabetic patients included in the study, 233 (72.8%; 95% confidence interval [CI]: 67.5–77.8) were found to have ED. Multivariable logistic regression analysis identified several factors significantly associated with ED: being in the age group of 40 to 49 years (adjusted odds ratios [AOR] = 5.91; 95% CI: 2.09–16.76), alcohol consumption (AOR = 3.79; 95% CI: 1.88–7.60), khat chewing (AOR = 2.44; 95% CI: 1.28–4.64), use of antihypertensive medication (AOR = 5.72; 95% CI: 1.57–20.86), low high-density lipoprotein cholesterol (AOR = 2.37; 95% CI: 1.23–4.57), elevated total cholesterol (AOR = 2.97; 95% CI: 1.33–6.65), and poor glycemic control (AOR = 2.68; 95% CI: 1.41–5.10). This study revealed a high prevalence of ED among male diabetic patients. The identified determinant factors should be carefully considered in the prevention, early detection, and management of ED in this population.

  • Open Access

    Prevalence and determinants of erectile dysfunction among type 2 diabetes mellitus patients at selected government hospitals in gurage zone: A cross-sectional study

    by Seid Abrar Abdlshikure, Aklilu Getachew Mamo, Bisrat Fikadu, Abdulber Seid

    Background: Erectile dysfunction (ED) is often not recognized in men with type 2 diabetes mellitus (T2DM), despite the prevalence of the disease. Early diagnosis of ED in T2DM is very important for effective treatment and prevention of serious complications such as cardiovascular events.This study investigates the prevalence and determinants of ED among T2DM patients at selected government hospitals in the Gurage Zone. Methods: We conducted a study in three public hospitals from September 1 to December 30, 2020. 204 diabetic men were selected using consecutive sampling. ED was evaluated utilizing the International Index of ED-5. Glycated hemoglobin (HbA1c) and lipid levels were analyzed utilizing a Cobas 600 clinical chemistry analyzer. The data was analyzed using the Statistical Package for Social Sciences-20. Results: ED was observed in 156 (76.5%) diabetic males. Independent predictors of ED included age above 40 years, alcohol consumption, khat chewing, overweight [Body mass index (BMI) ≥ 25 kg/m2], obesity (BMI ≥ 30 kg/m2), a diabetes duration of more than 5 years, uncontrolled diabetes (HbA1c > 7%), elevated low-density lipoprotein (LDL), and high total cholesterol levels (P < 0.05). Conclusion: The study confirmed a high prevalence of ED among males with T2DM in the study settings. Consequently, clinicians should adopt preventive measures and focus on identifying the factors associated with ED in these patients.


  • Open Access

    Dyslipidemia and Nutritional Status of HIV-Infected Children and Adolescents on Antiretroviral Treatment at the Comprehensive Chronic Care and Training Center of Jimma Medical Center

    by Tolera Ambisa Lamesa, Aklilu Getachew Mamo, Gebeyaw Arega Berihun, Regassa Alemu Kebede, Eba Bekele Lemesa, Waqtola Cheneke Gebisa

    Background: Highly active antiretroviral treatment is beneficial to suppress human immune virus replication in infected individuals. However, dyslipidemia and other metabolic abnormalities have emerged due to antiretroviral treatment. The prevalence of dyslipidemia in children and adolescents on antiretroviral treatment varies from 20% to 70%. The lack of data on children and adolescents in Ethiopia was the rationale for conducting this study. We aimed to determine prevalence of dyslipidemia and nutritional status in children and adolescents on follow-up at Jimma medical center. Materials and Methods: A hospital-based cross-sectional study was conducted with 150 children and adolescents on follow-up at Jimma medical center. A systematic sampling technique was employed. An interview was carried out to collect socioeconomic and demographic data and a review of medical records was carried out to collect patients’ clinical data. Anthropometric data were computed using the CDC growth chart. About 3– 5mL of fasting blood was collected to measure lipid profile. Multivariable logistic regression was performed to find the association between risk factors and lipid profile. Results: The overall prevalence of dyslipidemia in this study was 72%. About 72% and 21.3% of study subjects had low high-density lipoprotein and high triglyceride, respectively. Significant associations were observed between BMI for age ≤ 5% (AOR: 2.02, 95% CI: 1.14– 3.66; P=0.015) and low high-density lipoprotein; greater than 150 months on treatment (AOR: 1.02, 95% CI: 1.00– 1.03; P=0.01) and high triglyceride; and BMI for age ≤ 5% (AOR: 1.86, 95% CI: 1.03– 1.37; P=0.04) and high triglyceride. Conclusion: BMI for age < 5%, treatment duration of greater than 150 months, and parents’ educational level were significantly associated with dyslipidemia, so it is recommended that monitoring of those variables will help to reduce dyslipidemia and its complications in children and adolescents receiving treatment.


  • Open Access

    Validation of the International Consensus Group Criteria for Slide Review Following Automated Complete Blood Count at Jimma Medical Center, Ethiopia

    by Girum Tesfaye Kiya, Aklilu Getachew Mamo, Sintayehu Asaye Biya, Dejene Gebre Gobena, Natal Demeke, Tilahun Yemane Shenkutie

    Background: The international consensus group suggested criteria for action following automated complete blood count and white blood cell differential analysis. These criteria were set based on data from laboratories of developed countries. It is highly important to validate the criteria in developing countries where infectious diseases are still rampant that can affect blood cell count and morphology. Thus, this study aimed to validate the consensus group criteria for slide review at Jimma Medical Center, Ethiopia from November 1, 2020 to February 30, 2021. Methods: The study comprised a total of 1685 patient samples from the daily laboratory workload of CBC analysis. The samples were collected in K2-EDTA tubes (Becton Dickinson) and analyzed using Coulter DxH 800 and Sysmex XT-1880 hematology analyzers. A slide review was done on two Wright-stained slides for each sample. All statistical analyses were performed using SPSS version 20 software. Results: There were 39.8% positive findings, the majority of which were related to red blood cells. The false negative and false positive rates for Sysmex and Coulter analyzer were 2.4% vs 4.8%; and 4.6% vs 4.7%, respectively. The false negative rate was unacceptably higher when we used physicians’ triggered slide review, which was 17.3% and 17.9% for Sysmex and Coulter analyzers, respectively. Conclusion: Generally, the consensus group rules are suitable to use in our setting. However, we might still need to modify the rules, particularly to reduce the review rates. It is also necessary to confirm the rules with case mixes proportionally derived from the source population.


  • Open Access

    Lipid and Lipoprotein Profile in HIV-Infected and Non-Infected Diabetic Patients: A Comparative Cross-Sectional Study Design, Southwest Ethiopia

    by Shiferaw Woyesa, Aklilu Getachew Mamo, Zeleke Mekonnen, Gemeda Abebe, Esayas Kebede Gudina, Tesfaye Milkesa

    Background: Lipoproteins are complexes of lipids and proteins that are essential for the transport of cholesterol, triglycerides, and fat-soluble vitamins. The linkage between chronic diseases like diabetes mellitus and HIV infection increases the complication of the diseases and worsens the clinical outcome of the patients. Purpose: To assess and compare lipid and lipoprotein profiles among HIV-infected and non-infected diabetic patients, and to identify independent predictor variables for abnormal lipid and lipoprotein profiles. Patients and Methods: A comparative cross-sectional study design was used to carry out the research, and a convenient sampling technique was used to include 96 adult diabetic patients (48 HIV-infected and 48 non-infected diabetics). Socio-demographic and clinical data were collected by interviewer-administered questionnaire. Five milliliter blood sample was collected and processed for lipid and lipoprotein profile measurement. Multivariate and bivariate logistic regressions were used to identify independent predictor variables for abnormal lipid and lipoprotein profiles. Results: The prevalence of diabetic dyslipidemia was 41.7% and 37.5% in HIV-infected and non-infected diabetic patients, respectively. Hypercholesterolemia was more commonly detected among HIV-infected diabetic patients than non-HIV-infected, 25.0% versus 18.8%, respectively. Similarly, hypertriglyceridemia was more commonly observed in HIV-infected (31.3%) than non-infected diabetic patients (20.8%). About 25.0% HIV-infected diabetic patients had combined hyperlipidemia (hypercholesterolemia plus hypertriglyceridemia); and about 4.2% had hypoalphalipoproteinemia or isolated low HDL-C. Being female and long duration of diabetes mellitus were independent predictor variables for abnormal lipid and lipoprotein profiles in HIV-infected patients. Similarly, being female and high blood pressure were independent predictor variables in non-HIV-infected diabetic patients. Conclusion: High prevalence lipid and lipoprotein abnormalities were detected in HIV-infected diabetic patients even though the abnormalities were also common in non-HIV co-morbid diabetic patients. Hence, proactive screening and treatment of blood glucose, lipid, and lipoprotein abnormalities are critically important and should be part of comprehensive HIV care.